Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study

BACKGROUND: Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) was approved for treatment of diabetic macular edema (DME) after demonstration of its efficacy and safety in the MEAD registration trials. We performed subgroup analysis of MEAD study results to evaluate the efficacy and safety of DEX 0...

Descripción completa

Detalles Bibliográficos
Autores principales: Augustin, Albert J., Kuppermann, Baruch D., Lanzetta, Paolo, Loewenstein, Anat, Li, Xiao-Yan, Cui, Harry, Hashad, Yehia, Whitcup, Scott M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628378/
https://www.ncbi.nlm.nih.gov/pubmed/26519345
http://dx.doi.org/10.1186/s12886-015-0148-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628378/
https://www.ncbi.nlm.nih.gov/pubmed/26519345
http://dx.doi.org/10.1186/s12886-015-0148-2

Ejemplares similares